Mirati unveils its KRAS data at last
A thing smart people often say is that it’s foolish to make comparisons between clinical trials. And yet, a thing smart people often do is make comparisons between clinical trials.
With that in mind, yesterday the world finally got a look a cancer drug from Mirati Therapeutics, one whose promise gave the company a $3 billion valuation despite a total absence of any published data. That dollar figure was due mostly to Amgen, whose similar drug showed unprecedented results in lung cancer, and thus the conversation around Mirati indulged in the sin of cross-trial comparison.
As STAT’s Adam Feuerstein reports, Mirati’s drug was tested on fewer patients than Amgen’s, but the early returns look positive. Three of six lung cancer patients and one of four patients with colon cancer saw their tumors respond. That likely means Mirati is still competitive with Amgen, albeit with the major caveat that we’ll need to see lots more data before knowing whether either drug will actually become a product.
Read more.
With that in mind, yesterday the world finally got a look a cancer drug from Mirati Therapeutics, one whose promise gave the company a $3 billion valuation despite a total absence of any published data. That dollar figure was due mostly to Amgen, whose similar drug showed unprecedented results in lung cancer, and thus the conversation around Mirati indulged in the sin of cross-trial comparison.
As STAT’s Adam Feuerstein reports, Mirati’s drug was tested on fewer patients than Amgen’s, but the early returns look positive. Three of six lung cancer patients and one of four patients with colon cancer saw their tumors respond. That likely means Mirati is still competitive with Amgen, albeit with the major caveat that we’ll need to see lots more data before knowing whether either drug will actually become a product.
Read more.
.png)
No hay comentarios:
Publicar un comentario